Trials / Unknown
UnknownNCT04906473
Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors
A Phase Ⅰ Clinical Study of Single-arm, Open, Single/Multiple Dose Escalation and Dose Extension to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 109 (estimated)
- Sponsor
- Kunming Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
to assess the safety,tolerability, pharmacokinetic,pharmacodynamics and efficacy of KY100001 in patients with advanced solid tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KY100001 | KY100001; Tablet; Oral route; Dose escalation and dose extension |
Timeline
- Start date
- 2021-07-31
- Primary completion
- 2022-12-31
- Completion
- 2023-10-31
- First posted
- 2021-05-28
- Last updated
- 2021-05-28
Source: ClinicalTrials.gov record NCT04906473. Inclusion in this directory is not an endorsement.